Top Section/Ad
Top Section/Ad
Most recent
Offer came as markets recovered and volatility fell
Abbott Laboratories plundered $20bn as it led a trio of drug companies which printed jumbo bonds as a deluge of supply in the dollar market ensured a red-hot end to the month.
Eight banks provided loan facility to company
More articles/Ad
More articles/Ad
More articles
-
Swedish pharmaceutical company Oncopeptides has placed Skr1.1bn ($132m) of new shares to finance the commercialisation of its lead product candidate in the United States, and the development of other treatments. -
The rise in US Treasury yields in reaction to the government's $1.9tr stimulus package has prompted a shift in equity markets away from highly valued tech stocks that may do less well if interest rates rise as a result of higher inflation. But if the switch means investor portfolios reflect the wider economy, that is a positive development.
-
China’s YishengBio is planning to list in Hong Kong, having filed an IPO application with the bourse on Monday.
-
SK Bioscience has priced its IPO at the top of the marketed range, raising W1.49tr ($1.32bn) from South Korea’s largest listing in four years.
-
Colombia has increased its external funding programme for the year to over $10bn after forecasting a larger 2021 fiscal deficit than it recorded in 2020, exacerbating concerns about the government’s ability to maintain its investment grade credit rating.
-
Pablo de Ramón-Laca is director general of the treasury and financial policy at Spain's Ministry of Economic Affairs and Digital Transformation. That places him in charge of the world's ninth largest sovereign debt stock, according to S&P data, for a country pummelled by the Covid-19 pandemic. Spain has the second highest number of cases in the EU and the seventh highest in the world. But even that is not the full story of the pandemic's impact.
